Palvella Therapeutics is a biotechnology company based in Wayne, Pennsylvania, focused on developing and commercializing medicines for people with serious, rare skin diseases and vascular anomalies that lack FDA-approved treatments. Its mission is to address significant unmet medical needs, particularly in rare genetic skin diseases, where treatment options remain limited.

The company’s QTORIN™ platform is designed to deliver medicines topically, with the aim of achieving therapeutic drug concentrations while supporting chemical stability and minimizing absorption into the body. Palvella’s lead product candidate, QTORIN rapamycin, is a patented 3.9% anhydrous gel containing rapamycin, an mTOR inhibitor. It is being developed for microcystic lymphatic malformations, cutaneous venous malformations, and other serious skin diseases associated with mTOR pathway overactivation. The program includes a Phase 3 study for microcystic lymphatic malformations and a Phase 2 study for cutaneous venous malformations. QTORIN rapamycin has received FDA Breakthrough Therapy Designation for microcystic lymphatic malformations. Palvella’s work centers on advancing investigational therapies for patients with few or no existing treatment options.